Dr. Spreafico is Assistant Professor at the University of Toronto and Staff Medical Oncologist and Clinician Investigator in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre, University Health Network. Dr. Spreafico's previous training includes: a PhD in translational research in the Program for Evaluation of Targeted Therapies at the University of Colorado, USA, and a subspecialty fellowship in head and neck cancer and experimental therapeutics in the Bras Phase I Program at the Princess Margaret Cancer Centre. Dr. Spreafico is the Head and Neck Medical Oncology Disease Site Lead and Clinician Investigator within the Tumor Immunotherapy Program. She also serves as the Director of the Phase I Drug Development Fellowship at the Princess Margaret Cancer Centre.
Dr. Spreafico's full-time academic practice and her research focus on early drug development and phase I clinical trials, with disease-specific interests in melanoma, skin and head and neck cancers. Nationally and Internationally, Dr. Spreafico collaborates with major Institutions including Canadian Cancer Trials Group and the US NCI Cancer Therapy Evaluation Program. She is the Principal Investigator of numerous early phase, first-in-human and first-in-class trials and investigator-initiated biomarker-driven studies for which she holds large-scale peer review funding including the Canadian Cancer Society and Canadian Institutes of Health Research. She is the recipient of several national and international awards and, in the last five years, has published >50 peer-reviewed publications in widely cited journals.